Franz I W, Agrawal B, Wiewel D, Ketelhut R
Klinik Wehrawald der BfA, Todtmoos.
Clin Investig. 1992;70 Suppl 1:S53-7. doi: 10.1007/BF00207612.
The present study was conducted to assess the efficacy and safety of carvedilol 50 mg as compared to metoprolol 200 mg at rest and during and after a standardized bicycle ergometric exercise test. Carvedilol is a novel non-selective beta-blocker without intrinsic sympathomimetic activity possessing vasodilatory properties primarily due to an alpha 1-antagonism in the same dose range. Both drugs were effective in reducing systolic and diastolic blood pressure at rest and during and after exercise. The reduction of diastolic blood pressure was much stronger under carvedilol treatment than under metoprolol treatment at all measurement points. Carvedilol was even effective in the treatment of patients whose blood pressure was unsatisfactorily controlled by metoprolol. This shows the importance of the vasodilation component of carvedilol. No serious adverse events were observed. Carvedilol therefore promises very well as a powerful and safe drug for the treatment of essential arterial hypertension.
本研究旨在评估在静息状态以及标准化自行车测力计运动试验期间和之后,50毫克卡维地洛与200毫克美托洛尔相比的疗效和安全性。卡维地洛是一种新型非选择性β受体阻滞剂,无内在拟交感活性,在相同剂量范围内主要由于α1拮抗作用而具有血管舒张特性。两种药物在静息状态以及运动期间和之后均能有效降低收缩压和舒张压。在所有测量点,卡维地洛治疗下舒张压的降低比美托洛尔治疗下更强。卡维地洛对美托洛尔血压控制不佳的患者甚至也有效。这表明了卡维地洛血管舒张成分的重要性。未观察到严重不良事件。因此,卡维地洛有望成为一种强效且安全的原发性动脉高血压治疗药物。